It is suggested that, in SAS patients, downregulation of Cd38, Ryr2, and Fkbp12.6 may decrease the function of the Cd38–cADPR signaling in cardiomyocytes, leading to the failure of cardiac functions. This evidence concerns the gene CD38 and SATB2 associated disorder.